Latest News

FDA grants orphan drug status to lenabasum for dermatomyositis

The FDA has granted orphan drug designation to lenabasum for the treatment of dermatomyositis, a systemic autoimmune condition characterized by skin and muscle involvement, according to a press release from Corbus Pharmaceuticals.
An estimated 1 in 100,000 individuals in the United States are affected by dermatomyositis, according to the National Organization for Rare Disorders, with women disproportionately affected more than men and black, Asian and Native American populations exhibiting more severe morbidity.
Often characterized by distinct skin lesions accompanied by erosions,

Related posts

Sexual Assault Has Long-Term Mental, Physical Impact


Hospital workers across the U.S. present sharply different pictures of their preparedness for the coronavirus


Speed Keto For Weight Loss: Does It Work?


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy